• Endpoints beyond fracture promise to facilitate shorter trials, new osteoporosis research

    7 monthes ago - By Healio

    Osteoporotic fractures represent a costly human and socioeconomic burden. Even with currently available drugs, treatments that more effectively increase bone mineral density, reduce fractures and reverse the disease are needed.
    “Osteoporotic fractures, most notably hip fractures, cause substantial morbidity and mortality. In the osteoporosis scientific community, there is concern regarding the plateau or slight rise in hip fracture trends in the U.S., as well as a decline in the diagnosis and treatment of osteoporosis despite the treatment options available,” Theresa Kehoe, MD,
    Read more ...

     

  • Will BMD as sole endpoint be a competitive disadvantage for new osteoporosis drugs?

    7 monthes ago - By Healio

    Recent research from Dennis M. Black, PhD, makes a good case that the antifracture efficacy of antiresorptive osteoporosis medications can be reliably predicted from their effects on bone mineral density. This opens up the possibility of smaller and less expensive studies to determine the effectiveness of novel bone agents. However, there are a number of cautions that need to be borne in mind.
    The experience with fluoride made clear that increased BMD does not result in reduced fractures when the mineralization of bone is compromised. Therefore, good data on bone histology is a prerequisite
    Read more ...